Effect of Pravastatin on Serum Level of IL-6, Procalcitonin, and Duration to Clinical Improvement in Pneumonia Patients

· Biomolecular, Lung Infection

Jan Yanto Lydwines Purba,1,2 Reviono,1 Suradi,1 Harsini,1 Jatu Aphridasari1

1. Departemen Pulmonologi dan Kedokteran Respirasi Fakultas Kedokteran Universitas Sebelas Maret, RSUD Dr. Moewardi, Surakarta
2. Program Pasca Sarjana Minat Kedokteran Keluarga Biomedik Fakultas Kedokteran Universitas Sebelas Maret, RSUD Dr. Moewardi, Surakarta


Background: Pneumonia is an inflammatory disease caused by pathogen microbes. Inflamation reaction aimed to eliminate pathogen microbes but if the inflammation is ubiquitous and persistent, it can destroy structure and make dysfunction of pulmonary. Pravastatin has pleiotrophic effect as an antiinflamation, therefore the addition of it might control the inflammation and decrease the length of reaching clinical improvement.

Methods: This study was quasi-experimental with pre test and post test design. The subjects were pneumonia patient in Dr. Moewardi Hospital in February to April 2016. Thirty subjects were taken by consecutive sampling and divided into two groups, 15 subjects respectively.

Results: The Pro-CT median decreased from 1.66 (0.05 – 20) to 0.05 (0.02 – 16.02) in pravastatin group and the difference was significant statistically (p=0.015). The Pro-CT median decreased from 0.26 (0.05 – 80) to 0.14 (0.02 – 60.94) in control group and the difference was not significant statistically (p = 0.162). The median IL-6 increased from 13.31 (4.40 – 1025.25) to 15.47 (1.08 – 854.72) in pravastatin group and in control group 33.31 (1.56 – 981.15) to 57.79 (8.68 – 987.82) but the difference were not significant statistically. There was no significant difference statistically (p = 0.734) in median of time (day) that needed to reach clinical improvement between pravastatin group 4.00 (3.00 – 6.00) and control group 4.00 (3.00 – 6.00).

Conclusion: Pravastatin could to decrease the Pro-CT level but it does not have correlation with the IL-6 level and length of time of clinical improvement in pneumonia patients. (J Respir Indo. 2017;37:75-83)

Keywords: pravastatin, IL-6, procalcitonin, clinical improvement, pneumonia

Click here for full paper (PDF)